JP2023539361A5 - - Google Patents
Info
- Publication number
- JP2023539361A5 JP2023539361A5 JP2023514397A JP2023514397A JP2023539361A5 JP 2023539361 A5 JP2023539361 A5 JP 2023539361A5 JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023539361 A5 JP2023539361 A5 JP 2023539361A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- culture
- approximately
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073671P | 2020-09-02 | 2020-09-02 | |
| US63/073,671 | 2020-09-02 | ||
| PCT/US2021/071330 WO2022051749A1 (en) | 2020-09-02 | 2021-08-31 | Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539361A JP2023539361A (ja) | 2023-09-13 |
| JP2023539361A5 true JP2023539361A5 (enExample) | 2024-09-10 |
| JP7824934B2 JP7824934B2 (ja) | 2026-03-05 |
Family
ID=80492150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514397A Active JP7824934B2 (ja) | 2020-09-02 | 2021-08-31 | 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230265390A1 (enExample) |
| EP (1) | EP4204560A4 (enExample) |
| JP (1) | JP7824934B2 (enExample) |
| KR (1) | KR20230058167A (enExample) |
| CN (1) | CN116568805A (enExample) |
| AU (1) | AU2021337000A1 (enExample) |
| CA (1) | CA3191047A1 (enExample) |
| IL (1) | IL300903A (enExample) |
| WO (1) | WO2022051749A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP4649139A1 (en) * | 2023-02-01 | 2025-11-19 | Nkarta, Inc. | Methods for expanding immune cells and related compositions and uses thereof |
| KR102669705B1 (ko) * | 2023-02-24 | 2024-06-10 | 이엔셀 주식회사 | 제대혈 유래 자연 살해 세포의 확장배양방법 |
| KR20240175366A (ko) * | 2023-06-12 | 2024-12-20 | 한국화학연구원 | Nk 세포의 증식 촉진 또는 활성화용 조성물 및 그의 용도 |
| WO2025220989A1 (ko) * | 2024-04-16 | 2025-10-23 | 주식회사 유씨아이테라퓨틱스 | 자연살해세포의 증폭 및 형질 도입 효율 증진용 피더 세포 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7086928B2 (ja) * | 2016-07-25 | 2022-06-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
| US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
| KR102746901B1 (ko) * | 2017-03-03 | 2024-12-26 | 옵시디안 테라퓨틱스, 인크. | Cd19 조성물 및 면역요법을 위한 방법 |
| CA3056591A1 (en) * | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| US12473336B2 (en) * | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| CA3120563A1 (en) * | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| JP7724765B2 (ja) * | 2019-07-31 | 2025-08-18 | ンカルタ・インコーポレイテッド | ナチュラルキラー細胞の増殖を亢進する、および細胞障害性を増強するための方法および組成物 |
-
2021
- 2021-08-31 IL IL300903A patent/IL300903A/en unknown
- 2021-08-31 US US18/024,012 patent/US20230265390A1/en active Pending
- 2021-08-31 CN CN202180072917.0A patent/CN116568805A/zh active Pending
- 2021-08-31 EP EP21865294.9A patent/EP4204560A4/en active Pending
- 2021-08-31 CA CA3191047A patent/CA3191047A1/en active Pending
- 2021-08-31 KR KR1020237011188A patent/KR20230058167A/ko active Pending
- 2021-08-31 AU AU2021337000A patent/AU2021337000A1/en active Pending
- 2021-08-31 JP JP2023514397A patent/JP7824934B2/ja active Active
- 2021-08-31 WO PCT/US2021/071330 patent/WO2022051749A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539361A5 (enExample) | ||
| JP2022542399A5 (enExample) | ||
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Tarazona et al. | Current progress in NK cell biology and NK cell-based cancer immunotherapy | |
| JP2022184852A5 (enExample) | ||
| Ljunggren et al. | Prospects for the use of NK cells in immunotherapy of human cancer | |
| Locatelli et al. | Natural killer cells in the treatment of high-risk acute leukaemia | |
| Lim et al. | GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo | |
| van Ostaijen-ten Dam et al. | Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential | |
| RU2019128544A (ru) | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров | |
| JP2019523001A5 (enExample) | ||
| JP2017512484A5 (enExample) | ||
| JP2018500944A5 (enExample) | ||
| JP2016509839A5 (enExample) | ||
| CN111566201A (zh) | 使用用于表达嵌合抗原受体(car)或转基因t细胞受体(tcr)的病毒载体转导细胞的方法 | |
| JP2021522839A5 (enExample) | ||
| JP2012521215A5 (enExample) | ||
| JP5118624B2 (ja) | 新規なヒトｔ細胞集団 | |
| JP7572371B2 (ja) | 養子移入療法（Ａｄｏｐｔｉｖｅ ｔｒａｎｓｆｅｒ ｔｈｅｒａｐｉｅｓ）におけるＴリンパ球及びＮＫ細胞の拡大増殖及び分化のための方法 | |
| Barnes et al. | Making a killer: selecting the optimal natural killer cells for improved immunotherapies | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| JP2024513522A5 (enExample) | ||
| Velardi et al. | Lymphokine production by T-cell clones after human bone marrow transplantation | |
| Yang et al. | Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia | |
| CN115058393B (zh) | 一种包被刺激物、培养试剂盒和自然杀伤细胞的培养方法 |